Quantcast

Latest Diagnostic tests Stories

2010-03-04 07:00:00

SAN DIEGO, Calif., March 4 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing. CancerTYPE ID predicts cancer origin in patients whose primary cancer was initially "unknown or uncertain" using conventional diagnostics. Knowing the site...

2010-02-15 09:22:00

- Taking Steps to Preserve Liquidity - QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, today announced changes to its enterprise structure to optimize its growth potential. Henceforth, the Company will be comprised of two business segments: (1) administrative headquarters in Quebec City, holder of the PCA3, GCC and Shc patents, and (2)...

2010-02-09 07:30:00

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). (Logo:...

2010-01-14 16:44:00

QUEBEC CITY, Jan. 14 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, today reported financial and operation results for the fourth quarter 2009 and fiscal year ended October 31, 2009. The Company announced a net loss of $2,680,018 or $0.07 per share for the fourth quarter ending October 31, 2009, and a net loss of $12,865,055 or $0.30 per share for the fiscal year 2009. These results...

2010-01-11 07:00:00

SAN DIEGO, Jan. 11 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announced that the company has signed a three-year, exclusive agreement with Ferrer inCode to commercialize the bioTheranostics THEROS CancerTYPE ID® molecular cancer classifier in Spain, Portugal, Greece, and Venezuela. The agreement is effective immediately. Under the terms of the agreement, Spain-based...

2009-12-12 16:45:00

SAN DIEGO, Dec. 12 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test. Data from the studies were presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The THEROS Breast Cancer Index® (BCI) is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI),...

2009-11-18 06:05:00

BRENTWOOD, Tenn., Nov. 18 /PRNewswire/ -- With workers' compensation diagnostic imaging charges totaling billions of dollars a year, more employers are looking for ways to control the cost of on-the-job injuries while ensuring that employees return to work quickly and safely. ADIN Healthcare, Inc. offers solutions to employers with a national network of diagnostic providers, evidence-based guidelines and process oriented service delivery. In conjunction with one of its major payers,...

2009-11-09 15:00:00

SAN DIEGO, Nov. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today reported its financial results for the quarter ended September 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) Third Quarter Results Total revenue for the third quarter of 2009 was $9.2 million, compared with $11.6 million for the third quarter of 2008. Cost of product and service revenue for the third quarter of 2009 was $2.7 million, compared with $4.5 million for the third quarter...

2009-11-02 14:44:00

SILVER SPRING, Md., Nov. 2 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today published a guidance document that should help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus. Although there are not any FDA-approved or cleared tests that diagnose this specific infection, during this pandemic manufacturers can submit a request to the FDA for an Emergency Use Authorization (EUA). If granted, the EUA will allow the test to be used during the national...

2009-10-29 12:51:00

NEW YORK, Oct. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Molecular Diagnostics: A Dynamic and Rapidly Broadening Market http://www.reportlinker.com/p0156566/Molecular-Diagnostics-A-Dynamic-and-Rapidly-Broadening-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Molecular diagnostic applications in the areas of oncology, personalized medicine, inherited disorders, prediction of genetic...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related